<DOC>
	<DOC>NCT02260791</DOC>
	<brief_summary>The purpose of the study is to compare the effectiveness and safety of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have inadequate disease control on methotrexate.</brief_summary>
	<brief_title>A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. Male or female aged 18 years or over 2. Patients have been diagnosed with Rheumatoid Arthritis (RA) for at least 3 months 3. Patient has active RA 4. Patient has taken a stable dose of methotrexate for at least 3 months 1. Patient has been previously treated with adalimumab 2. Patient has been previously treated or has ongoing treatment with prohibited medications 3. Patient has been immunised with a live or attenuated vaccine in past 4 weeks 4. Patient has positive result for HIV, HBV, HCV or TB infection Other Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rheumatoid</keyword>
	<keyword>Arthritis</keyword>
</DOC>